Select Your Region
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Trial Finder
- IMvigor130
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Bladder Cancer Urothelial Carcinoma
Basic Details
Sponsor
Hoffmann-La Roche
Phase
Phase 3
Trial Identifier
NCT02807636, WO30070, 2016-000250-35
Condition
Urothelial Carcinoma
Official Title
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Trial Summary
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
Eligibility Criteria
All
≥ 18 Years
No
Inclusion Criteria
- Considered to be eligible to receive platinum-based chemotherapy, in the investigator's judgment
- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (</=) 2
- Histologically documented, locally advanced (T4b, any N; or any T, N2-3) or metastatic urothelial carcinoma (mUC) (M1, Stage IV) (also termed transitional cell carcinoma [TCC] or urothelial cell carcinoma [UCC] of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra)
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor PD-L1 expression prior to study enrollment; participants who have fewer than 15 unstained slides available at baseline (but no less than [<] 10) may be eligible following discussion with the Medical Monitor
- No prior chemotherapy for inoperable locally advanced or mUC
- For participants who received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial carcinoma, a treatment-free interval more than (>) 12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment naive in the metastatic setting
- Prior local intravesical chemotherapy or immunotherapy is allowed if completed at least 4 weeks prior to the initiation of study treatment
- Measurable disease, as defined by RECIST v1.1
- Adequate hematologic and end-organ function
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of carboplatin, cisplatin, or gemcitabine or for 5 months after the last dose of atezolizumab
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm
Exclusion Criteria
- Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
- Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrolment
- Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic assessments
- Participants with treated asymptomatic central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria: * Evaluable or measurable disease outside the CNS * No metastases to midbrain, pons, medulla, or within 10 mm of the optic apparatus (optic nerves and chiasm) * No history of intracranial or spinal cord hemorrhage * No ongoing requirement for corticosteroid as therapy for CNS disease; anti-convulsants at a stable dose are allowed * No evidence of significant vasogenic edema * No stereotactic radiation, whole-brain radiation or neurosurgical resection within 4 weeks prior to Cycle 1, Day 1 * Radiographic demonstration of interim stability (i.e., no progression) between the completion of CNS-directed therapy and the screening radiographic study * Screening CNS radiographic study >/=4 weeks since completion of radiotherapy or surgical resection and >/=2 weeks since discontinuation of corticosteroids
- Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
- Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1, Day 1 or anticipated requirement for systemic immunosuppressive medications during the study
- Leptomeningeal disease
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
- Uncontrolled tumour-related pain or hypercalcemia
- Significant cardiovascular disease including known left ventricular ejection fraction (LVEF) <40%
- Severe infections within 4 weeks before randomization or therapeutic oral or IV antibiotics within 2 weeks before randomization
- Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
- Malignancies other than urothelial carcinoma within 5 years prior to Cycle 1, Day 1
- Life expectancy of <12 weeks
- Pregnant or lactating, or intending to become pregnant during the study
- Serum albumin <25 gram per liter (g/L)
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
- History of autoimmune disease
- Participants with prior allogeneic stem cell or solid organ transplantation
- History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
- Positive test for human immunodeficiency virus (HIV)
- Active hepatitis B or hepatitis C
- Active tuberculosis
- Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
Study results
IMvigor130_LPS_ 2020May_English
(PDF, 0.6 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Bosnia
(PDF, 0.9 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Brazil
(PDF, 0.8 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Chile
(PDF, 0.2 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Chinese_Hong Kong
(PDF, 1.3 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Czech_Republic
(PDF, 0.7 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_English_Hong Kong
(PDF, 0.9 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Estonia
(PDF, 1.1 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Finland
(PDF, 0.4 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_French_Belgium
(PDF, 1.0 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Georgia
(PDF, 0.6 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Greece
(PDF, 0.9 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Israel
(PDF, 0.9 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Italy
(PDF, 0.5 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Japan
(PDF, 1.0 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Korea
(PDF, 0.8 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Mexico
(PDF, 0.4 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Netherlands
(PDF, 0.2 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Netherlands_Belgium
(PDF, 0.8 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Poland
(PDF, 1.2 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Portugal
(PDF, 1.0 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Romania
(PDF, 0.9 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Russia
(PDF, 1.0 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Russian_Ukraine
(PDF, 1.0 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Slovenia
(PDF, 1.5 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Spain
(PDF, 0.8 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Taiwan
(PDF, 1.2 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Thailand
(PDF, 1.0 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_Ukraine
(PDF, 0.7 MB)
LPS_WO30070_IMvigor130_final results_23Feb2022_United kingdom
(PDF, 0.9 MB)
LPS_WO30070_IMvigor130_final results_16March2020_Singapore
(PDF, 1.8 MB)
LPS_WO30070_IMvigor130_final results_November2019_Spain
(PDF, 0.8 MB)
LPS_WO30070_IMvigor130_final results_November2019_Turkey
(PDF, 0.6 MB)
LPS_WO30070_IMvigor130_final results_November2019_China
(PDF, 0.7 MB)
LPS_WO30070_IMvigor130_final results_November2019_Serbia
(PDF, 1.2 MB)
LPS WO30070 IMvigor130 Final Results May 2023 English
(PDF, 1.3 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com